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Summary
Purpose: As a prelude to developing updated, evidence-based, international consensus recommendations for the management of hip and
knee osteoarthritis (OA), the Osteoarthritis Research Society International (OARSI) Treatment Guidelines Committee undertook a critical
appraisal of published guidelines and a systematic review (SR) of more recent evidence for relevant therapies.
Methods: Sixteen experts from four medical disciplines (primary care two, rheumatology 11, orthopaedics one and evidence-based medicine
two), two continents and six countries (USA, UK, France, Netherlands, Sweden and Canada) formed the guidelines development team. Three
additional experts were invited to take part in the critical appraisal of existing guidelines in languages other than English. MEDLINE, EMBASE,
Science Citation Index, CINAHL, AMED, Cochrane Library, seven Guidelines Websites and Google were searched systematically to identify
guidelines for the management of hip and/or knee OA. Guidelines which met the inclusion/exclusion criteria were assigned to four groups of
four appraisers. The quality of the guidelines was assessed using the AGREE (Appraisal of Guidelines for Research and Evaluation) instru-
ment and standardised percent scores (0e100%) for scope, stakeholder involvement, rigour, clarity, applicability and editorial independence,
as well as overall quality, were calculated. Treatment modalities addressed and recommended by the guidelines were summarised. Agree-
ment (%) was estimated and the best level of evidence to support each recommendation was extracted. Evidence for each treatment modality
was updated from the date of the last SR in January 2002 to January 2006. The quality of evidence was evaluated using the Oxman and
Guyatt, and Jadad scales for SRs and randomised controlled trials (RCTs), respectively. Where possible, effect size (ES), number needed
to treat, relative risk (RR) or odds ratio and cost per quality-adjusted life year gained (QALY) were estimated.
Results: Twenty-three of 1462 guidelines or consensus statements retrieved from the literature search met the inclusion/exclusion criteria. Six
were predominantly based on expert opinion, ﬁve were primarily evidence based and 12 were based on both. Overall quality scores were 28%,
41% and 51% for opinion-based, evidence-based and hybrid guidelines, respectively (P¼ 0.001). Scores for aspects of quality varied from
18% for applicability to 67% for scope. Thirteen guidelines had been developed for speciﬁc care settings including ﬁve for primary care
(e.g., Prodigy Guidance), three for rheumatology (e.g., European League against Rheumatism recommendations), three for physiotherapy
(e.g., Dutch clinical practice guidelines for physical therapy) and two for orthopaedics (e.g., National Institutes of Health consensus guide-
lines), whereas 10 did not specify the target users (e.g., Ontario guidelines for optimal therapy). Whilst 14 guidelines did not separate hip
and knee, eight were speciﬁc for knee but only one for hip. Fifty-one different treatment modalities were addressed by these guidelines,
but only 20 were universally recommended. Evidence to support these modalities ranged from Ia (meta-analysis/SR of RCTs) to IV (expert
opinion). The efﬁcacy of some modalities of therapy was conﬁrmed by the results of RCTs published between January 2002 and 2006. These
included exercise (strengthening ES 0.32, 95% conﬁdence interval (CI) 0.23, 0.42, aerobic ES 0.52, 95% CI 0.34, 0.70 and water-based ES
0.25, 95% CI 0.02, 0.47) and nonsteroidal anti-inﬂammatory drugs (NSAIDs) (ES 0.32, 95% CI 0.24, 0.39). Examples of other treatment mo-
dalities where recent trials failed to conﬁrm efﬁcacy included ultrasound (ES 0.06, 95% CI 0.39, 0.52), massage (ES 0.10, 95% CI 0.23,
0.43) and heat/ice therapy (ES 0.69, 95% CI 0.07, 1.45). The updated evidence on adverse effects also varied from treatment to treatment.
For example, while the evidence for gastrointestinal (GI) toxicity of non-selective NSAIDs (RR¼ 5.36, 95% CI 1.79, 16.10) and for increased
risk of myocardial infarction associated with rofecoxib (RR¼ 2.24, 95% CI 1.24, 4.02) were reinforced, evidence for other potential drug related
adverse events such as GI toxicity with acetaminophen or myocardial infarction with celecoxib remained inconclusive.
Conclusion: Twenty-three guidelines have been developed for the treatment of hip and/or knee OA, based on opinion alone, research evidence
or both. Twenty of 51 modalities of therapy are universally recommended by these guidelines. Although this suggests that a core set of recom-
mendations for treatment exists, critical appraisal shows that the overall quality of existing guidelines is sub-optimal, and consensus recommen-
dations are not always supported by the best available evidence. Guidelines of optimal quality are most likely to be achieved by combining
research evidence with expert consensus and by paying due attention to issues such as editorial independence, stakeholder involvement
and applicability. This review of existing guidelines provides support for the development of new guidelines cognisant of the limitations in ex-
isting guidelines. Recommendations should be revised regularly following SR of new research evidence as this becomes available.
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Osteoarthritis (OA) is the most common form of arthritis and
a major contributor to functional impairment and reduced in-
dependence in older adults1. The hip and knee are the princi-
pal large joints affected by OA. Although estimates of the
prevalence of hip and knee OA vary considerably depending
on whether the disease is deﬁned by both symptoms and ra-
diographic changes, or by radiographic criteria alone, knee
OA is more prevalent2e6 than hip OA7e11. Overall, as many
as 40% of those aged over 65 in the community may have
symptomatic OA of the knee or hip12,13. Current treatment
strategies with both non-pharmacologic and pharmacologic
therapies aim to reduce pain, physical disability and handi-
cap, and some of themattempt to limit structural deterioration
in affected joints. Surgical therapies are available for patients
who fail to respond tomore conservativemeasures14,15. In re-
cent years, both the American College of Rheumatology
(ACR) and the European League against Rheumatism (EU-
LAR) have developed recommendations to optimise the
treatment of hip and/or knee OA based on a variable combi-
nation of expert consensus and systematic review (SR) of re-
searchevidence16e18. Although theseguidelinesare usedby
physicians, funding authorities and government agencies in
order to try and improve the quality of care of patients with
knee and hip OA, they have been criticised for lack of meth-
odological rigour, stakeholder involvement and applicabili-
ty19e21; and the recommendations for certain modalities of
treatment that they contain may require modiﬁcation follow-
ing publication of more recent randomised controlled trials
(RCTs) and meta-analyses (MAs). The Osteoarthritis Re-
search Society International (OARSI) therefore appointed
an international, multidisciplinary committee of experts in
September 2005 with the remit of producing up to date, evi-
dence-based, globally relevant consensus recommenda-
tions for the management of hip and/or knee OA in 2007.
The committee undertook a critical appraisal of existing evi-
dence-based and consensus guidelines and an SR of the
current research evidence; as a prelude to developing con-
sensus recommendations following a Delphi exercise. This
paper reports the results of the critical appraisal of existing
treatment guidelines and the SR of the more recent research
evidence. The purpose of this study was to identify the evi-
dence available, assess its quality and to use this knowledge
to develop a new guideline. Part II of this document: ‘‘The
OARSI evidence-based consensus recommendations for
the treatment of OA of the hip and knee’’ will be published
separately in Osteoarthritis and Cartilage.
Methods
PARTICIPANTS
The guideline development committee was composed of
16 experts from four medical disciplines (primary care two,
rheumatology 11, orthopaedics one, and evidence-based
medicine two) and six countries in Europe and North
America (France, Netherlands, Sweden, UK, Canada
and the USA). All members of this guideline development
team participated in: (1) a critical appraisal of existing
treatment guidelines; (2) a Delphi exercise to generate
consensus recommendations; and (3) an exercise to
grade the strength of recommendation for all modalities
of therapy recommended. Three additional experts were
invited to undertake critical appraisals of existing guide-
lines in languages other than English.CRITICAL APPRAISAL OF EXISTING GUIDELINES
Systematic literature search
A systematic literature search for existing guidelines for
the management of hip and/or knee OA published in any
language between 1945 and October 2005 was undertaken
using MEDLINE (1966e), EMBASE (1980e), CINAHL
(1980e), AMED (1985e) and the Science Citation Index
(1945e). The search strategy consisted of two basic com-
ponents: guidelines in any term (e.g., guidelines, recom-
mendations, standards, algorism, or expert consensus,
etc.) and hip or knee OA in any possible terms in the data-
bases (Appendix 1). In addition, Google (the ﬁrst 100 hits)
and seven Guideline Websites were searched, including
the National Guideline Clearinghouse http://www.guideli-
nes.gov/, Primary Care Clinical Practice Guidelines http://
medicine.ucsf.edu/resources/guidelines/, the Scottish Inter-
collegiate Guidelines Network http://www.sign.ac.uk/,
the Canadian Medical Association Infobase for Clinical
Practice Guidelines http://mdm.ca/cpgsnew/cpgs/index.
asp, the Guidelines International Network http://www.g-i-n.
net/, Evidence Based Medicine Guidelines http://www.
ebm-guidelines.com/, and the National Institute for Clinical
Excellence http://www.nice.org.uk/.
Inclusion/exclusion criteria
Guidelines developed for the management of hip and/or
knee OA using consensus or evidence-based methods
were included. The latest version was included if the guide-
lines had been updated. Guidelines developed for OA in
other joints or for aspects of OA other than treatment
were excluded, as were narrative reviews, commentaries
and appraisals of implementation.
Quality and content assessment
English language guidelines were randomly assigned to
three groups of four committee members for appraisal of
quality and content. Three guidelines published in German
and Dutch were appraised by three additional experts who
were ﬂuent in these languages. The quality of the guidelines
was assessed using the AGREE instrument22, in which 23
criteria in seven domains are evaluated. These include the
scope and purpose of the guidelines, stakeholder participa-
tion, methodological rigour, clarity, applicability, editorial in-
dependence and overall quality. The content was extracted
using a comprehensive reference list of treatment modali-
ties. Each appraiser scored the guidelines independently
and results were collected and analysed by the lead inves-
tigator (WZ) and the co-chairs (GN and RM), who did not
take part in the assessment.
Data analyses
The appraisers’ scores from each group were expressed
as standardised domain scores on a percentage scale
(0e100%)22. Guidelines were categorised according to
the methods (expert opinion based, research evidence
based or both), the target users to whom they were directed
(primary care, rheumatology, physiotherapy or orthopae-
dics), the scope of the recommendations (general and spe-
ciﬁc treatments) and the joints for which the guidelines were
applicable (hip, knee, or hip and knee). Quality scores were
compared between groups using an analysis of variance
(ANOVA). Agreement (%) between guidelines was calcu-
lated by
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where Nr is the number of guidelines recommending the
modality and Na indicates number of guidelines addressing
the modality. Levels of evidence were examined and for
each modality, the best available evidence was selected
according to the evidence hierarchy (Table I)23.
SR OF RECENT EVIDENCE
Systematic literature search
A systematic search of the literature published between 31
January 2002 and 31 January 2006 was undertaken using
MEDLINE, EMBASE, CINHAL, AMED, the Science Citation
Index and the Cochrane Library databases. Research evi-
dence prior to January 2002 was not sought systematically
as this was available from the systematic literature review
conducted by EULAR17. Separate searches for research ev-
idence for each treatment modality were undertaken. Each
search was conducted sequentially according to the evi-
dence hierarchy (SRs/MAs, followed by RCTs/controlled
trials (CTs), quasi-experimental and uncontrolled studies)
(Table II)23. An example of how this search strategy was
employed to obtain the best available research evidence
for the efﬁcacy of acetaminophen (paracetamol) is shown
in Appendix 2. The same strategy was used for searching
MEDLINE, EMBASE, CINHAL and AMED. For the Science
Citation Index, however, a key word search was used and
all possible terms and combinations of terms were tied in
order to obtain relevant citations. Medical subject heading
searches (MeSH) were used for all databases and key
word searches were used if a MeSH search was not avail-
able. All MeSH search terms were exploded. The reference
lists of SRs were examined and any additional studies meet-
ing the inclusion/exclusion criteria were included.
The search in the Cochrane Library included MeSH
searches of Cochrane reviews, abstracts of Quality As-
sessed Systematic Reviews, the Cochrane Controlled Trial
Register, the National Health Service (NHS) Economic
Evaluation Databases, the Health Technology Assessment
Database and the NHS Economic Evaluation Bibliography
Details Only. In addition, a comprehensive search for all ar-
ticles including the term OA regardless of treatment was
undertaken.
Inclusion/exclusion criteria
Only studies with clinical outcomes for hip and/or knee
OA were included. The main focus was on SRs/MAs,
RCTs/CTs, uncontrolled trials, cohort studies, caseecontrol
studies, cross-sectional studies and economic evaluations.
Studies of OA at other sites such as the hand or spine, and
other chronic joint diseases were excluded, apart from
Table I
Evidence hierarchy23
Ia MA of RCTs
Ib RCT
IIa Controlled study without randomisation
IIb Quasi-experimental study
III Non-experimental descriptive studies, such as comparative,
correlation, and caseecontrol studies
IV Expert committee reports or opinion or clinical
experience of respected authorities, or bothstudies in which adverse effects of relevant pharmacologic
treatments were being investigated as a primary outcome.
Case reports, animal studies, non-clinical outcome studies,
narrative review articles, commentaries and guidelines were
excluded.
The efﬁcacy of any modality of treatment was determined
by using the best available evidence. For example, when the
efﬁcacy of an intervention could be conﬁrmed by category Ia
evidence (MA/SR of RCTs), then studies lower in the
evidence hierarchy such as individual RCTs (category Ib)
were not reviewed (Table I). If there was more than one
study in the same evidence level (e.g., four SRs for
NSAIDs), the study with the best quality score was used. In-
formation concerning side effects was obtained from both
RCTs and observational studies. While the efﬁcacy of
each therapeutic intervention was assessed separately for
hip and knee OA, side effects were evaluated for each inter-
vention regardless of the OA therapy and the target joint.
For determination of cost effectiveness, only cost-utility
analyses were included.
Quality assessment
The quality of SR/MAs was assessed using the Oxman
and Guyatt checklist24 and the quality of RCTs was evalu-
ated using the Jadad method25. All quality scores were con-
verted into percentages of the maximum score attainable.
Quality assessments were not undertaken for other types
of study designs, such as cohort or caseecontrol studies.
For cost-utility analysis, study perspective, comparator,
time horizon, discounting, modelling and uncertainty were
evaluated.
Outcome measures
Efficacy. Effect sizes (ESs) and 95% conﬁdence intervals
(CIs) compared with placebo or active control were calcu-
lated for continuous outcomes such as reduction of pain
from baseline or improvement in function26. ES is the stan-
dard mean difference, i.e., the mean difference between
Table II
23 existing guidelines for the management of hip and/or knee OA
N Guidelines
Type of guidelines
Opinion based 6 Royal College of Physicians, etc.
Evidence based 5 Prodigy Guidance, etc.
Both 12 EULAR, etc.
Topic
General 13 ACR, EULAR, etc.
Speciﬁc 10 MOVE, Canadian NSAIDs, etc.
Target joint(s)
Hip 1 EULAR
Knee 8 German, etc.
Both 14 ACR, etc.
Target users
Primary care 5 Prodigy Guidance, etc.
Rheumatology 3 EULAR, etc.
Physiotherapy 3 Dutch physiotherapy, etc.
Orthopaedics 2 NIH consensus, etc.
Not speciﬁed 10 Ontario, ICSI, etc.
Language
English 21 ACR, EULAR, etc.
Others 2 German, Malay, etc.
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deviation of the difference. It is expressed as a number
without units and can be used for comparisons across all
interventions. From the clinical standpoint ESs of 0.2 are
considered small and 0.5 moderate, while an ES> 0.8
indicates a large clinical effect27. Statistical pooling was un-
dertaken, as appropriate, when SRs were not available28.
For dichotomous data, such as the percentage of patients
with moderate to excellent (or more than 50%) pain relief
or symptomatic improvement, the number needed to treat
(NNT) was estimated29. The NNT is the estimated number
of patients who need to be treated to achieve the target
effect. Thus the smaller the NNT the better the treatment
effect. The 95% CI for the NNT was calculated using
Altman’s method30.
Side effects. The relative risk (RR) of side effects was calcu-
lated from RCTs or cohort studies for the incident risk, and
from cross-sectional studies for prevalent risk. Odds ratios
(ORs) were calculated from caseecontrol studies31. Both
RR and OR provide information on how many times more
likely (or less likely) it is that a subject who is exposed to
a treatment modality will have an adverse event, when com-
pared with a subject who is not exposed. An RR/OR¼ 1 indi-
cates no increased risk, whereas an RR/OR> 1 or <1
indicates increased or decreased risk, respectively.
Cost effectiveness. Only cost-utility analysis was reviewed,
where cost per quality-adjusted life years (QALYs) gained
was used. Costs were converted into US dollars and values
were discounted by 5% per year from the year in which the
study was published until 2006.
Data were extracted by two investigators (WZ and a re-
search assistant, Jane Robertson). A customised form
was used for data extraction and quality assessment. Any
discrepancies were discussed and agreed between the
extractors prior to analysis. The data from the non-English
language studies were extracted by assessors with good
understanding of the languages concerned.
Results
QUALITY AND CONTENTS OF EXISTING GUIDELINES
The systematic literature search yielded 1462 cita-
tions (MEDLINE 276, EMBASE 413, CINAHL 81, AMED
27 and SCI 553, Google and Guidelines Websites 112).
Of these, 23 met the inclusion and exclusion criteria
speciﬁed16e18,32e51. Six guidelines were predominantly
based on opinion, ﬁve primarily based on evidence and
12 based on both (Table II). Whilst the majority of the guide-
lines14 did not separate hip and knee, eight were speciﬁc for
knee but only one for hip OA. Thirteen guidelines had been
developed for speciﬁc care settings (ﬁve for primary care,
three for rheumatology, three for physiotherapy and two
for orthopaedics); but 10 did not specify target users.
Scores for overall quality of guidelines were 28%, 41% and
51% for opinion-based, evidence-based and hybrid guide-
lines, respectively (P< 0.001) (Fig. 1). Scores for different
quality criteria varied but apart from applicability, opinion-
based guidelines tended to have lower scores (Table III).
Fifty-one treatment modalities were addressed in the 23
guidelines. Twenty of these modalities were recommended
by all (100%) of the guidelines in which they were ad-
dressed (Table IV), but the strength of agreement for
any modality appeared to be related to the number ofguidelines that addressed that modality. For example,
while regular telephone contact and knee fusion were
recommended in 100% of the guidelines in which these
modalities of therapy were considered, this was actually
in only two guidelines for each modality. By contrast, al-
though weight loss was not universally recommended, it
was in fact recommended in 13/14 of the guidelines where
this modality was considered.
Evidence to support recommendations ranged from Ia
(SR of RCTs) to IV (expert opinion), and did not necessarily
reﬂect the extent of agreement (Table IV). For example,
while canes/sticks, total joint replacement and osteotomy
were not supported by RCTs, they were still universally rec-
ommended in the guidelines which addressed them. In con-
trast, despite evidence from SRs of RCTs for the efﬁcacy of
chondroitin sulphate and ultrasound, they were recommen-
ded by <50% of the guidelines in which these modalities
were considered (Table IV).
RECENT EVIDENCE
The results of the SR of research papers published
between January 2002 and January 2006 are shown in
Table V.
Efficacy
With the exception of combination therapy, the use of
a cane/stick and referral, all the non-pharmacologic and
pharmacologic therapies recommended universally by ex-
isting guidelines were supported by recent SRs of RCTs
(Ia) or RCTs (Ib) published after 2002. By contrast, there
were no placebo controlled trials of surgical modalities of
treatment such as total joint replacement and osteotomy,
and supporting evidence came from uncontrolled or non-ex-
perimental observational studies (Table V). Overall quality
scores for evidence ranged between 40% and 100% but
24/40 studies (60%) scored 100% (Table V).
TheES for pain relief scores varied fromsmall (e.g., educa-
tion ES¼ 0.06, 95%CI 0.02, 0.10) to moderate (e.g., aerobic
exercise ES¼ 0.52, 95% CI 0.34, 0.70). No modality of
therapy had an ES as high as 0.80 e the accepted criterion
for a large clinical effect27 (Fig. 2). ESs for pain relief score
with oral analgesics such as acetaminophen (ES¼ 0.21
95% CI 0.02, 0.41) and NSAIDs (ES¼ 0.32, 95% CI 0.24,
0.39) were small (Fig. 3 and Table V).
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Fig. 1. Overall quality score of guidelines (mean S.E.M.).
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Quality scores (%)
Mean S.E.M.
Opinion based Evidence based Hybrid P
n 6 5 12
Scope 45.90 7.30 79.26 8.00 74.23 5.37 0.007
Stakeholder 17.36 6.12 30.56 8.62 37.27 4.42 0.058
Rigour 14.68 5.29 28.57 11.39 57.80 5.57 <0.001
Clarity 42.66 4.60 68.19 10.35 63.14 10.35 0.026
Applicability 15.48 6.47 12.78 4.78 21.53 2.14 0.313
Editorial 19.25 6.30 24.72 7.84 50.58 7.33 0.013
Overall 26.09 4.48 40.68 4.24 50.76 2.70 <0.001
S.E.M.: standard error of mean.ESs for improvement in function were also generally
small, and very similar to those for pain relief, for a number
of modalities of non-pharmacological therapies (Table V).
However, the ES for improvement in function for >10%
weight reduction was 0.69 (95% CI 0.24, 1.14) compared
with the ES for pain relief (0.13, 95% CI 0.12, 0.38).
ESs for reduction in stiffness were also available for a few
modalities of treatment (Table V).
Some studies provided data, which allowed calculation
of NNTs. For example, weight reduction (>10%) was as-
sociated with an NNT of three (95% CI 2, 9), i.e., one in
three patients with knee OA who achieved this loss of
weight would have more than 50% reduction in the total
Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis index52. The NNT for topical NSAIDs was
also three (95% CI 2, 4), indicating that one in threepatients with pain associated with knee OA treated with
a topical NSAID would be expected to experience moder-
ate to excellent pain relief53.
In general, non-pharmacologic therapies had numerically
smaller ES (ES¼ 0.25, 95% CI 0.16, 0.34) than pharmaco-
logical therapies (ES¼ 0.39, 95% CI 0.31, 0.47) (Figs. 2
and 3). Among surgical treatments, ES could only be calcu-
lated for arthroscopic lavage and debridement. An SR of
four RCTs showed that arthroscopic joint lavage and de-
bridement were no more effective than placebo54. One pla-
cebo controlled RCT (with a quality score of 100%) included
in this review demonstrated that the ES for arthroscopic la-
vage and debridement vs placebo were 0.09 (95% CI
0.27, 0.44) and 0.01 (95% CI 0.37, 0.35), respec-
tively55. Similar results were obtained for improvement in
function (Table V). Although there are no placebo controlledTable IV
Agreement and level of evidence for modalities of therapy recommended by existing guidelines*
Level of evidencey Agreement (number of guidelines recommending the modality/total number of guidelines addressing the modality)
<25% 25%e 50%e 75%e 100%
Ia Ultrasound (1/5) Chondroitin
sulphate (2/7)
Heat/ice (7/10)
Glucosamine
sulphate (6/10)
NSAIDþ
H2-blockers
(5/8)
NSAIDs (15/16)
Insole (12/13)z
Braces (8/9)z
Topical capsaicin
(8/9)z
IA HA (8/9)z
IA steroid (11/13)z
TENS (8/10)
Topical NSAIDs (7/9)z
Aerobic exercise (21/21)
Strengthening exercise (21/21)
Acetaminophen (16/16)
Education (15/15)
COX-2 inhibitors (11/11)
Opioid (9/9)
Self-management (8/8)
Water-based exercise (8/8)
NSAIDþPPI (8/8)
NSAIDþmisoprostol (8/8)
Telephone (2/2)
Ib Laser (1/6) Nutrients
(1/3)
Acupuncture
(5/8)
Weight loss (13/14) Combination therapy (12/12)
Electrotherapy/EMG
(1/8)
Massage (1/2) Patellar tape (12/13) Joint lavage (3/3)
Diacerhein (1/2) Avocado soybean
unsaponiﬁables (3/4)
Herbs (2/2)
III TJR (14/14)
Osteotomy (10/10)
IV Oral steroid (0/2) Arthroscopic
debridement (5/6)
Cane/stick (11/11)z
Referral (5/5)
Knee fusion (2/2)z
Knee aspiration (2/2)z
TENS¼ Transcutaneous Electrical Nerve Stimulation; EMG¼Electromyography; TJR¼ Total Joint Replacement.
*Modalities were grouped according to strength of agreement and level of evidence. Modalities addressed by only one guideline were not
included, such as radiotherapy, sauna/spa, gait aid, topical rubefacients, oestrogen, patellar resurfacing, and anti-depressants. Modalities not
directly related to the treatment such as consideration of risk factors, clinical features, etc. were excluded.
yLevel of evidence: Ia¼SR of RCTs; Ib¼RCT, IIa¼CT; IIb¼ quasi-experiment; III¼ cohort/caseecontrol study; and IV¼ expert opinion.
Only the highest level of evidence has been selected for each modality.
zSpeciﬁc for knee OA.
Sstiffness (95% CI) NNT (95% CI)
17 (0.05, 0.39)64
NS93
NS
36 (0.08, 0.80)52 3 (2, 9)52
2 (1, 5)97
4 (2, 17)98
.83(0.03, 1.69)101
r swelling
41 (0.13, 0.69)63 4 (3, 9)63
2 (1, 2)106
49 (0.17, 0.80)53 3 (2, 4)53
4 (3, 5)109
4 (2, 11)110
06 (0.11, 0.23)113 5 (4, 7)114
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Recent evidence for efficacy of treatment of hip and knee OA
Modality Joint QoS (%) LoE Recent evidence (2002e)
ESpain (95% CI) ESfunction (95% CI) E
General
Risk factors
Clinical phase
Combination therapy
Non-pharmacological
Self-management Both 100 Ia 0.06 (0.02, 0.10)89 0.06 (0.02, 0.10)89
Telephone Both 100 Ia 0.12 (0.00, 0.24)90 0.07 (0.00, 0.15)90
Education Both 100 Ia 0.06 (0.02, 0.10)89 0.06 (0.02, 0.10)89
Strengthening Knee 100 Ia 0.32 (0.23, 0.42)91 0.32 (0.23, 0.41)91
Aerobic Knee 100 Ia 0.52 (0.34, 0.70)91 0.46 (0.25, 0.67)91
Water-based exercise Both 60 Ib 0.25 (0.02, 0.47)64,92 0.23 (0.00, 0.45)64 0.
Balneotherapy Knee 75 Ia
Spa/sauna Both 75 Ib 0.46 (0.17, 0.75)94
Weight reduction Knee 40 Ib 0.13 (0.12, 0.38)52,95 0.69 (0.24, 1.14)52 0.
Nutrients (e.g., SAM-e) Knee 100 Ia 0.22 (0.25, 0.69)96 0.31 (0.10, 0.52)96
TENS Both 75 Ia
Laser Both 100 Ia
Ultrasound Both 50 Ia 0.06 (0.39, 0.52)99
Radiotherapy Both 50 IIb Similar effects between OA and RA from an MA of uncontrolled trial100
Heat/ice Knee 75 Ia 0.69 (0.07, 1.45)101 1.03 (0.44, 1.62)101
for quads strength;
1.13 (0.54, 1.73)101
for ﬂexion
0
fo
Massage Knee 40 Ib 0.10 (0.23, 0.43)102
Acupuncture Knee 40 Ib 0.51 (0.23, 0.79)63 0.51 (0.23, 0.79)63 0.
Insoles Knee 100 Ia No different between type of insoles, no placebo/usual care comparisons103
Cane/stick
Joint protection (braces) Knee 100 Ia More beneﬁts with a knee brace than a neoprene sleeve103
Electrotherapy/EMG Knee 75 0.77 (0.36, 1.17)104
Referral
Pharmacological
Acetaminophen Both 100 Ia 0.21 (0.02, 0.41)105
NSAIDs Both 100 Ia 0.32 (0.24, 0.39)107
NSAIDsþPPIs OA/RA 100 Ia
NSAIDsþH2 blockers OA/RA 100 Ia
NSAIDsþmisoprostol OA/RA 100 Ia
COX-2 inhibitors Both 100 Ia 0.44 (0.33, 0.55)108
(exc Deek’s for OA/RA)
Topical NSAIDs Knee 100 Ia 0.41 (0.22, 0.59)53 0.36 (0.24, 0.48)53 0.
Topical capsaicin Knee 75 Ia
Opioids Both 50 Ia
Other narcotics
Oral steroid
IA Corticosteroid Knee 100 Ia 0.72 (0.42, 1.02)110 0.06 (0.17, 0.30)110
IA Hyaluronic acid Knee 100 Ia 0.32 (0.17, 0.47)111 0.00 (0.23, 0.23)112
Glucosamine sulphate Both 100 Ia 0.61 (0.28, 0.95)113 0.07 (0.08, 0.21)113 0.
Chondroitin sulphate Knee 100 Ia 0.52 (0.37, 0.67)114
Diacerhein Both e Ib 0.22 (0.01, 0.42)81e85
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.RCTs of total joint (knee or hip) replacement or osteotomy,
two recent SRs of uncontrolled trials and cohort studies con-
ﬁrmed that they were highly effective in relieving pain and im-
proving quality of life56,57.
Side effects
Evidence for side effects of treatments has been mainly
investigated in pharmacologic therapies. Oral NSAIDs
were associated with 3e5 times the risk of gastrointesti-
nal (GI) side effects when compared with placebo or
non-exposure58, whereas treatment with topical NSAIDs
resulted in no more adverse GI events than placebo
(RR¼ 0.81, 95% CI 0.43, 1.56)53 or non-exposure
(OR¼ 1.45, 95% CI 0.84, 2.50)59 (Table VI). Whether or
not long-term treatment with acetaminophen 4 g daily is
associated with GI and renal side effects remains incon-
clusive (Table VI). Treatment with cyclooxygenase-2
(COX-2) selective drugs or conventional non-selective
NSAIDs together with proton pump inhibitors (PPIs) or mi-
soprostol has been shown to be associated with a reduc-
tion in the risk of NSAID-induced upper GI side effects.
However, treatment with rofecoxib has been shown to
be associated with an increased risk of cardiovascular
(CV) events (RR¼ 2.24, 95% CI 1.24, 4.02)60 and treat-
ment with misoprostol with an increased risk of diarrhoea
(RR¼ 1.81, 95% CI 1.52, 2.61)61. Following the with-
drawal of rofecoxib, a number of RCTs and SRs of the
CV safety of other coxibs and conventional non-selective
NSAIDs have been undertaken. While the increased risk
of CV side effects with rofecoxib was conﬁrmed, the evi-
dence for similar CV toxicity with celecoxib, valdecoxib
and conventional non-selective NSAIDs was inconsistent
(Table VI). However, the overall CV risk associated with
COX-2 selective inhibitors was not signiﬁcantly greater
than that associated with conventional non-selective
NSAIDs (RR¼ 1.19, 95% CI 0.80, 1.75)62 (Table VI).
Cost effectiveness
Four cost-utility analyses have been undertaken since
2002. One in Germany, in which acupuncture was com-
pared with sham acupuncture63; two in the UK, which stud-
ied treatment with water-based exercises and GI protective
strategies64,65; and one in Canada, which looked at treat-
ment with intra-articular injections of hyaluronic acid66.
Two previous studies which had compared total hip and
knee replacements with conventional pharmacologic and
non-pharmacologic therapy were retrieved for comparison
purpose67,68. Cost/QALY varied with modalities, countries,
comparators, perspectives, time horizons and discounting
rates and remained variable, even after adjustment for dis-
counting and conversion of the original cost per QALY to
the current value of the US dollar (Table VII).
Discussion
Clinical guidelines are frequently deﬁned as ‘systemati-
cally developed statements to assist practitioner and patient
decisions about appropriate health care for speciﬁc clinical
circumstances’69. OA is the most prevalent form of arthritis
throughout the world1e7 and OA related knee pain is the
leading cause of physical disability in older adults1.The
prevalence of both symptomatic and radiographically de-
ﬁned hip OA7e11 is less than that of knee OA2e6 and varies
from one country to another7,8,70. The treatment of
988 W. Zhang et al.: OARSI recommendations for the management of hip and knee OASummary meta-analysis plot [random effects]
-1.0 -0.5 0.0 0.5 1.0 1.5
combined 0.25 (0.16, 0.34)
Acupuncture 0.51 (0.23, 0.79)
Massage 0.10 (-0.23, 0.43)
Heat/ice 0.69 (-0.07, 1.45)
Electrotherapy/EMG 0.77 (0.36, 1.17)
Ultrasound 0.06 (-0.39, 0.52)
Nutrients (eg, SAM-e) 0.22 (-0.25, 0.69)
Weight reduction 0.13 (-0.12, 0.38)
Spa/sauna 0.46 (0.17, 0.75)
Water-based exercise 0.25 (0.02, 0.47)
Aerobic exercise 0.52 (0.34, 0.70)
Strengthening exercise 0.32 (0.23, 0.42)
Education 0.06 (0.02, 0.10)
Telephone 0.12 (0.00, 0.24)
Self management 0.06 (0.02, 0.10)
* difference (95% confidence interval)
Fig. 2. ES for pain relief with non-pharmacological therapies.symptomatic OA of the knee and hip are global problems,
which present challenges to the clinical skills and judge-
ment of health professionals everywhere. As there is no sin-
gle treatment modality which will relieve pain, improve
mobility and prevent structural progression of disease, ef-
fective management relies on the appropriate use of a num-
ber of available therapies, each of which has only limited
efﬁcacy. While a number of national and regional guidelines
have been developed to assist physicians and other health
professionals in their management of hip and/or knee
OA16e18,32e51, there are currently no universally agreedrecommendations, even for a core group of safe and effec-
tive therapies, that can be recommended for the treatment
of OA of the knee and hip throughout the world. As a prelude
to developing updated, evidence-based, international,
expert consensus recommendations for the management
of hip and knee OA, the OARSI Treatment Guidelines Com-
mittee undertook a critical appraisal of existing published
guidelines and an SR of more recent evidence for relevant
therapies. The purpose of these preliminary appraisals was
(1) to establish the extent to which different modalities of
therapy are recommended in existing guidelines, and toSummary meta-analysis plot [random effects]
0.0 0.3 0.6 0.9 1.2
combined 0.39 (0.31, 0.47)
Diacerhein 0.22 (0.01, 0.42)
Chondroitin Sulphate 0.52 (0.37, 0.67)
Glucosamine Sulphate 0.61 (0.28, 0.95)
IA Hyaluronic acid 0.32 (0.17, 0.47)
IA Corticosteroid 0.72 (0.42, 1.02)
Topical NSAIDs 0.41 (0.22, 0.54)
COX-2 inhibitors 0.44 (0.33, 0.55)
NSAIDs 0.32 (0.24, 0.39)
Acetaminophen 0.21 (0.02, 0.41)
* difference (95% confidence interval)
Fig. 3. ES for pain relief with pharmacological therapies.
989Osteoarthritis and Cartilage Vol. 15, No. 9explore the possibility that there may be a core set of rec-
ommendations common to all the guidelines; (2) to investi-
gate the extent to which these guidelines are based on
available research evidence; (3) to assess the quality of
the guidelines using the widely accepted AGREE criteria;
and (4) to examine the extent to which more recent re-
search evidence conﬁrms, or fails to conﬁrm, recommenda-
tions in existing guidelines.
Table VI
Safety profiles e RR or OR* and 95% CI
Interventiony Adverse events RR/OR (95% CI) Evidence (references)
Acupuncture Any 0.76 (0.13, 4.42) RCT63
Acetaminophen GI discomfort 0.80 (0.27, 2.37) RCTs105
GI perforation/bleed 3.60 (2.60, 5.10) CC118
GI bleeding 1.2 (0.8, 1.7) CCs119
Renal failure 0.83 (0.50, 1.39) CS120
Renal failure 2.5 (1.7, 3.6) CC121
NSAIDs GI perforation/ulcer/bleed 5.36 (1.79, 16.10) RCTs58
GI perforation/ulcer/bleed 2.70 (2.10, 3.50) CSs58
GI perforation/ulcer/bleed 3.00 (2.70, 3.70) CCs58
Myocardial infarction 1.09 (1.02, 1.15) CSs122
Topical NSAIDs GI events 0.81 (0.43, 1.56) RCTs53
GI bleed/perforation 1.45 (0.84, 2.50) CC59
H2 blockerþNSAID vs NSAID Serious GI complications 0.33 (0.01, 8.14) RCTs62
Symptomatic ulcers 1.46 (0.06, 35.53) RCTs62
Serious CV or renal events 0.53 (0.08, 3.46) RCTs62
PPIþNSAID vs NSAID Serious GI complications 0.46 (0.07, 2.92) RCTs62
Symptomatic ulcers 0.09 (0.02, 0.47) RCTs62
Serious CV or renal events 0.78 (0.10, 6.26) RCTs62
MisoprostolþNSAID vs NSAID Serous GI complications 0.57 (0.36, 0.91) RCTs62
Symptomatic ulcers 0.36 (0.20, 0.67) RCTs62
Serious CV or renal events 1.78 (0.26, 12.07) RCTs62
Diarrhoea 1.81 (1.52, 2.61) RCTs61
COX-2 inhibitors
Coxibs vs NSAID Serious GI complications 0.55 (0.38, 0.80) RCTs62
Symptomatic ulcers 0.49 (0.38, 0.62) RCTs62
Serious CV or renal events 1.19 (0.80, 1.75) RCTs62
Celecoxib Myocardial infarction 2.26 (1.0, 5.1) RCTs123
Myocardial infarction 0.97 (0.86, 1.08) CSs/CCs122
Rofecoxib Myocardial infarction 2.24 (1.24, 4.02) RCTs60
Myocardial infarction 1.27 (1.12, 1.44) CSs/CCs122
Valdecoxib CV events 2.3 (1.1, 4.7) RCTs124
Opioids Any 1.4 (1.3, 1.6) RCTs125
Constipation 3.6 (2.7, 4.7) RCTs125
Glucosamine sulphate Any 0.97 (0.88, 1.08) RCTs113
Diacerhein Diarrhoea 3.98 (2.90, 5.47) RCTs81,85
H2-blockers: histamine type 2 receptor antagonists.
*RR: Relative Risk; OR: Odds Ratio; CC: caseecontrol study; CS: cohort study. Pooled RR/OR was provided if more than one study were
included.
yCompared with placebo/non-exposure unless otherwise stated.
Table VII
Cost per QALY
Intervention Comparator Perspective* Time horizon Discounting Year published Country Cost/QUALY
Original Converted ($)y
Water-based exercise Usual care Societal 1 Year No 2005 UK £5738 1048364
Acupuncture Sham acupuncture Societal 3 Months No 2005 Germany 17845 V 2229763
NSAIDþPPI NSAIDs NHS 6 Months No 2005 UK £33889 6191565
NSAIDþmisoprostol NSAIDs NHS 6 Months No 2005 UK £8889 1624065
COX-2 speciﬁcs NSAIDs NHS 6 Months No 2005 UK £36923 7429865
COX-2 selectives NSAIDs NHS 6 Months No 2005 UK £30000 6036765
Intra-articular
hyaluronic acid
Standard care Societal 1 Year No 2002 Canada $10000 1045366
Total hip replacement Conventional
therapy
Societal Life 5% 1996 US $4754 813167
Total knee replacement Pre-operation Institutional 2 Years No 1997 US $5856 1032568
*Perspective¼ perspective for economic evaluation (Societal¼ costs and beneﬁts to whole society; NHS¼ costs and beneﬁts to UK
National Health Service; Institutional¼ costs and beneﬁts to other payers, e.g., insurance company).
yThe original Cost/QALY was converted into US$ with a discount rate of 5% pa from the date of the publication to the current value on 10
March 2006.
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GUIDELINES, CORE RECOMMENDATIONS AND
THEIR EVIDENCE BASE
The critical appraisal of the 23 existing guidelines
showed that of 51 treatment modalities addressed, 20
were universally recommended in those guidelines in which
they were considered (100% agreement in Table IV).
These included recommendations for non-pharmacological
modalities of therapy such as education, exercise, patient
contact by telephone and provision of walking aids and
pharmacological treatments such as acetaminophen, non-
selective NSAIDs with co-prescription of gastroprotective
agents or selective COX-2 inhibitors, opioids and some
herbal remedies. Surgical treatments recommended in all
the guidelines in which they were considered included
knee aspiration and joint lavage as well as osteotomy,
knee fusion and total joint replacements. Self-management
and the combination of non-pharmacologic and pharmaco-
logic treatments were also uniformly recommended core
recommendations. It is apparent that this core set of recom-
mended therapies must reﬂect the availability of treatments.
The less than universal recommendation for some modali-
ties of therapy may have been a consequence of them not
being universally available, e.g., topical NSAIDs and avo-
cado soybean unsaponiﬁables are available in Europe but
not in the USA. It is also important to consider the number
of guidelines, which considered any particular modality of
therapy in ones interpretation of the reliability of the
strength of agreement for that treatment. Clearly, the conﬁ-
dence one can have in the universal recommendation for
exercise, where this modality of treatment was considered
and endorsed in 21/21 guidelines, is likely to be greater
than the conﬁdence one has in the recommendation for
knee fusion, which was only considered and endorsed in
2/2 guidelines.
It was also apparent that some of the core set of univer-
sally recommended therapies were not supported by evi-
dence from RCTs. For example, while exercise of various
types was supported by SR of RCTs (level Ia), total joint re-
placement was only supported by uncontrolled or cohort
studies (level III) and the recommendations for knee aspira-
tion and knee fusion were based on expert opinion (level IV).
The extent to which RCTs should be the gold standard for the
recommendation of all treatments has been the subject of
previous discussion and controversy71,72. Nevertheless,
the level of research evidence and clinical effectiveness
have been important considerations in the development of
recent guidelines for the treatment of knee and hip OA17,18
and in the development of the OARSI recommendations.
Clearly guidelines based on recommendations for treat-
ments for which there is proven evidence of beneﬁt should
at least have the potential for improving clinical outcomes
and the quality of health care for patients, although suc-
cess is certainly not guaranteed and evidence-based
guidelines are only one option for improving the quality
of health care.
A pilot survey of the perceived usefulness of the treat-
ment modalities addressed by the existing guidelines was
conducted among physicians and other health care profes-
sionals attending a New York University e OARSI Rheu-
matology Symposium in 2006. The purpose of the survey
was to collect the users’ opinions on the usefulness of cur-
rent treatment guidelines. The usefulness of each recom-
mended treatment modality was assessed by the
participants using a 5-point categorical scale (not useful,
slightly useful, moderately useful, very useful andabsolutely essential). Votes (%) on ‘‘very useful or abso-
lutely essential’’ were calculated. Of 19 participants who
completed the questionnaire (four general physicians, eight
rheumatologists, one physiotherapist, one orthopaedic sur-
geon, one pharmacist and four other health professionals),
94% perceived total joint replacement to be very useful or
essential therapy for both knee OA and hip OA. Combina-
tion therapy was judged to be very useful or essential by
79% for knee OA and 72% for hip OA. Weight reduction
was perceived to be more useful for knee than hip OA
by 68%, whereas NSAIDs, NSAID plus PPIs, COX-2 inhib-
itors, self-management, education and exercise were con-
sidered useful for both hip and knee OA. Although this
survey was far from being truly representative of all poten-
tial guideline users and only involved a very small number
of participants, most of whom were from the United States,
the views expressed about the usefulness of various mo-
dalities of treatment were at least consistent with the ap-
praisal of existing guidelines that has led to the deﬁnition
of a tentative core set of recommended treatment modali-
ties. It also points to a possible way of assessing the po-
tential applicability of any future recommendations for
other modalities of therapy being considered as additions
to this core set.
QUALITY OF EXISTING GUIDELINES
The methodology involved in the development of treat-
ment guidelines for OA has evolved considerably in the
last decade. Between the publication of the ﬁrst guide-
lines for the treatment of OA by the Royal College of
Physicians in 199349 and the publication of the EULAR
recommendations in 200518, the paradigm has shifted
from purely opinion-based guidelines49 to entirely evi-
dence-based guidelines such as the Prodigy Guidance34
and subsequently to hybrid guidelines based on both re-
search evidence and clinical expertise such as the EU-
LAR recommendations17,18. However, no attempt had
been made to try and assess the quality of these guide-
lines. We have therefore used the AGREE instrument to
evaluate the quality of all existing guidelines for scope
and purpose, stakeholder participation, methodological
rigour, clarity, applicability, editorial independence and
overall quality22. Overall quality was better in evidence-
based than opinion-based guidelines, and signiﬁcantly
better still in the hybrid guidelines that combined re-
search evidence with expert opinion (Fig. 1). This is
mainly attributable to the improved scores for scope
and purpose (P¼ 0.007), rigour of development
(P< 0.001) and editorial independence (P¼ 0.013) in
the hybrid guidelines (Table III). There is a tendency
for evidence-based guidelines to have lower
applicability, although the differences are not statistically
signiﬁcant (Table III). This may, in part, reﬂect the gap
that exists between RCTs which demonstrate that an in-
tervention works (‘‘efﬁcacy’’) and how often and well the
intervention works in clinical practise (‘‘clinical effective-
ness’’). Hybrid guidelines can be expected to demon-
strate improved applicability as clinical expertise can
temper the rigidity of research data and close the gap
between research and clinical practise.
In the development of hybrid guidelines by the EULAR
OA Task Force, expert consensus on the most important
propositions was followed by a systematic search for pub-
lished supporting research evidence, prior to assigning
a strength and conﬁdence of recommendation for each
treatment proposition. These were based on combined
991Osteoarthritis and Cartilage Vol. 15, No. 9consideration of the research evidence and clinical exper-
tise after also considering risks and beneﬁts, including po-
tential adverse effects and the cost of each treatment
modality18. This method is clinically driven and evidence
supported. The sequence of steps has been modiﬁed
slightly for the development of the OARSI Treatment Guide-
lines. An initial SR of research evidence was followed by the
development of expert consensus based on a combined
consideration of the research evidence and the clinical ex-
pertise of the members of the committee. This was then fol-
lowed by assignment of strength and conﬁdence of
recommendation for each proposition as before. This cur-
rent method is evidence-driven and clinically supported. An-
other important difference in the methodology used in the
development of the OARSI recommendations has been
that the committee has not arbitrarily restricted the number
of treatment options that it would consider, as was the case
in the development of the EULAR guidelines17,18.
LIMITATIONS
There are a number of limitations to this study.
Firstly it was inevitably necessary to set ﬁxed timelines
for the literature search, i.e., from January 2002 to January
2006. Evidence before this time was obtained from the
EULAR SR. For technical reasons it has not been possible,
to date, to pool the data, so that the SRs of the relevant
scientiﬁc literature before January 2002 and from January
2002 to January 2006 remain as two separate data sets.
Evidence that has been published after January 2006
has yet to be systematically reviewed. There have been
a number of new studies published after 31 January
2006, examples are those for glucosamine, chondroitin, di-
acerhein and self-management73e77. It has not been possi-
ble to update the SR following the Delphi exercise, which is
described in detail in the second part of this report. The
methods used to develop the guideline involved undertak-
ing an SR of the research evidence to inform and assist in
the development of the expert consensus. Any new evi-
dence or proposals for changes in the consensus recom-
mendations after completion of the Delphi exercise
should properly be considered in the context of the full ev-
idence and propositions. This would have required another
systematic literature search for all evidence and a further
Delphi exercise, which would not have been feasible within
the timeframe. Sensitivity analysis78 was therefore under-
taken to examine whether these recently published studies
would alter any of the evidence-based conclusions
(Table VIII). For example, the results of two further RCTsfor glucosamine hydrochloride, The National Institutes of
Health Glucosamine/Chondroitin Arthritis Intervention
(GAIT) Trail and sulphate (GUIDE) Trial have recently
been published74,75. The addition of the data from these
two studies to the main body of trial outcomes did not alter
ESs for glucosamine sulphate or hydrochloride signiﬁ-
cantly. Treatment with glucosamine sulphate remained su-
perior to placebo while treatment with glucosamine
hydrochloride was not. However, following the addition of
the new data on chondroitin sulphate from the GAIT study
to the results of the earlier RCTs, treatment with chondroi-
tin sulphate was no longer superior to placebo74,76 (Table
VIII). However, there are a number of studies that have
been reported in 2007 that have not been included, two
examples are trials of chondroitin sulphate and of weight
reduction which were published after the analyses and dis-
cussion for this manuscript were completed79,80. Treatment
with diacerhein was the subject of a recent Cochrane SR77.
The calculations of ES and RR were similar to those found
in this study (Table VIII). No attempt has been made to
pool the data as the majority of trials included in the Co-
chrane review are already included in our main analy-
sis81e85. A new RCT of self-management (class training
package plus educational booklets) vs educational book-
lets alone did not show any difference for the WOMAC
pain scores between groups73. Unfortunately, numerical
data were not available and a sensitivity test could not
be conducted.
As it is of course almost certain that additional studies,
which may be relevant to the analyses and conclusions
contained in this report, will be published in due course,
we plan to review accumulating evidence annually, and to
formally update the guidelines as required within 3e5
years.
Secondly, research evidence can be prone to publica-
tion bias. Although we have searched Cochrane library,
unpublished/unregistered trials cannot be comprehen-
sively assessed. We would therefore encourage investi-
gators to register any trials that are being undertaken or
planned.
Thirdly, caution must be taken when looking for cross-
treatment comparisons unless the evidence has been
obtained from a direct comparison. Most of the evidences
summarised in this report are from placebo controlled
studies. Placebo effects may vary across trials and
indirect comparison can be misleading86. In addition,
there are numerous differences between trials such as
differences in study period, severity of disease, age, gen-
der and co-morbidities, etc. For example it is not appro-
priate to make a direct comparison of ESs betweenTable VIII
Sensitivity analyses
Modality Outcome measure(s) Point estimate (95% CI)
Data 2002e2006 Data 2006e Pooled
Glucosamin sulphate ESpain 0.68 (0.32, 1.04) 0.26 (0.01, 0.54)75 0.45 (0.04, 0.86)
Glucosamin hydrocloride ESpain 0.13 (0.27, 0.53) 0.03 (0.18, 0.13)74 0.01 (0.15, 0.14)
Chondroitin sulphate ESpain 0.52 (0.37, 0.67) 0.02 (0.18, 0.14)74 0.30 (0.10, 0.70)
0.42 (0.04, 0.79)76
Diacerhein ESpain 0.22 (0.01, 0.42) 0.22 (0.01, 0.42)
77 NA
RRdiarrhoea 3.98 (2.90, 5.47) 3.81 (2.54, 5.71)
77
Self-management ESpain 0.06 (0.02, 0.10) No difference for
WOMAC pain73
NA: not applicable as the new study is an updated SR.
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NSAIDs (ES¼ 0.32, 95% CI 0.24, 0.39) and to draw
the conclusion that electrotherapy is more effective than
NSAIDs.
Finally, evidence was selected sequentially according to
the evidence hierarchy (Table I) and the quality of the stud-
ies, and only the best available evidence was considered.
Whether this is an adequate approach is open to discus-
sion. An MA is not necessarily superior to a large scale
well-conducted RCT87, and RCTs are not necessarily better
than observational studies88. Differences in the underlying
populations being examined may also impact the results
of a study.
In summary, a critical appraisal of existing treatment
guidelines across countries and regions has identiﬁed
a core set of treatments for the management of hip and
knee OA. The quality and applicability of these guidelines
increased when research evidence and expert opinions
were combined. The study suggests that there is room
for improvement in the quality and applicability of guide-
lines for the management of hip and knee OA in the future.
Regular SR of research evidence and update of recom-
mendations are important to ensure that guidelines remain
current.
Acknowledgements
The authors would like to thank Jane Robertson for work on
the literature search, data extraction and database develop-
ment, Joanna Ramowski for guideline collection and digiti-
sation, and Diann Stern and Helen Richardson for
logistics support throughout the project. We also thank Pro-
fessors Leo Van de Putte, Frank Wollheim and Burkhard
Leeb for their participations in quality and content assess-
ment of the non-English guidelines. Financial support
came from OARSI.
Conflicts of interest: Full disclosure statements from all
members of the OARSI treatment guidelines committee
are shown in Appendix 3. These have been reviewed
by the OARSI ethics committee. No potential conﬂict of
interest was identiﬁed that should preclude the participa-
tion of any member of the committee in this critical
appraisal.
Members of the OARSI treatment guidelines committee
Chair: George Nuki, Queen’s Medical Research Institute,
University of Edinburgh, Edinburgh, UK.
Co-chair: Roland W. Moskowitz, University Hospitals,
Case Western Reserve University, Cleveland, OH,
USA.
Lead investigator: Weiya Zhang, Academic Rheumatology,
Nottingham City Hospital, University of Nottingham,
Nottingham, UK.
Members: Steve Abramson, Hospital for Joint Diseases,
New York University School of Medicine, New York, NY,
USA.
Roy D. Altman, University of California at Los Angeles,
Agua Dulce, CA, USA.
Nigel K. Arden, Medical Research Council, Southampton
General Hospital, Southampton, UK.
Sita Bierma-Zeinstra, Erasmus Medical Center, Rotterdam,
Netherlands.
Kenneth D. Brandt, Indiana University School of Medicine,
Indianapolis, IN, USA.
Peter Croft, Keele University, Keele, UK.Michael Doherty, Academic Rheumatology, Nottingham
City Hospital, University of Nottingham, Nottingham, UK.
Maxime Dougados, Hopital Cochin, Paris, France.
Marc Hochberg, University of Maryland School of Medicine,
Baltimore, MD, USA.
David J. Hunter, Boston University School of Medicine,
Boston, MA, USA.
Kent Kwoh, University of Pittsburgh Department of Medi-
cine, Pittsburgh, PA, USA.
Stefan Lohmander, Department of Orthopaedics, Lund
University Hospital, Lund, Sweden.
Peter Tugwell, Institute of Population Health, University of
Ottawa, Ottawa, Canada.
Appendix 1. Search strategy for guidelines e example
from MEDLINE
Database: Ovid MEDLINE(R) <1966 to October Week 2 2005>
Search strategy
1 guideline$.mp. or exp Practice Guideline/
(106190)
2 recommendation$.mp. (61755)
3 standard$ of care.mp. (5830)
4 practice standard$.mp. or exp Professional
Standard/ (3195)
5 exp Algorithm/or clinical algorithm$.mp. (55742)
6 practice algorithm.mp. (15)
7 clinical guideline$.mp. (2325)
8 expert$ consensus.mp. (332)
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (218508)
10 hip osteoarthritis.mp. or exp hip Osteoarthritis/or exp
hip arthrosis/(2534)
11 hip osteoarthrosis.mp. (23)
12 coxarthritis.mp. or exp coxitis/(55)
13 osteoarthritis.mp. or exp OSTEOARTHRITIS/
(30570)
14 osteoarthrosis.mp. (2401)
15 osteophyte.mp. or exp OSTEOPHYTE/(682)
16 joint space narrowing.mp. (534)
17 degenerative joint disease$.mp. (1304)
18 hip pain.mp. (837)
19 hip.mp. or exp HIP/(61176)
20 13 or 14 or 15 or 16 or 17 (32523)
21 19 and 20 (6981)
22 10 or 11 or 12 or 18 or 21 (7688)
23 knee osteoarthritis.mp. or exp knee Osteoarthritis/
(2966)
24 knee osteoarthrosis.mp. (41)
25 gonarthritis.mp. (104)
26 knee pain.mp. or exp knee pain/(1580)
27 osteoarthritis.mp. or exp OSTEOARTHRITIS/
(30570)
28 osteoarthrosis.mp. (2401)
29 osteophyte.mp. or exp OSTEOPHYTE/(682)
30 joint space narrowing.mp. (534)
31 degenerative joint disease$.mp. (1304)
32 27 or 28 or 29 or 30 or 31 (32523)
33 knee.mp. or exp KNEE/(60576)
34 32 and 33 (9001)
35 23 or 24 or 25 or 26 or 34 (10200)
36 22 or 35 (16242)
37 9 and 36 (289)
38 remove duplicates from 37 (280)
39 limit 38 to human (276)
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Database: Ovid MEDLINE(R) <2002 to January Week 1 2006>
Search strategy
1 hip osteoarthritis.mp. or exp hip Osteoarthritis/or
exp hip arthrosis/(1716)
2 hip osteoarthrosis.mp. (11)
3 coxarthritis.mp. or exp Coxitis/(15)
4 osteoarthritis.mp. or exp OSTEOARTHRITIS/
(14265)
5 osteoarthrosis.mp. (764)
6 osteophyte.mp. or exp OSTEOPHYTE/(365)
7 joint space narrowing.mp. (365)
8 degenerative joint disease$.mp. (521)
9 hip pain.mp. (501)
10 hip.mp. or exp HIP/(27430)
11 4 or 5 or 6 or 7 or 8 (15077)
12 10 and 11 (2892)
13 1 or 2 or 3 or 9 or 12 (3290)
14 knee osteoarthritis.mp. or exp Knee
Osteoarthritis/(3035)
15 knee osteoarthrosis.mp. (20)
16 gonarthritis.mp. (45)
17 knee pain.mp. or exp Knee Pain/(1096)
18 osteoarthritis.mp. or exp
OSTEOARTHRITIS/(14265)
19 osteoarthrosis.mp. (764)
20 osteophyte.mp. or exp OSTEOPHYTE/(365)
21 joint space narrowing.mp. (365)
22 degenerative joint disease$.mp. (521)
23 18 or 19 or 20 or 21 or 22 (15077)
24 knee.mp. or exp KNEE/(26787)
25 23 and 24 (5157)
26 14 or 15 or 16 or 17 or 25 (5922)
27 13 or 26 (8262)
28 exp Meta-Analysis/or systematic
review.mp. (10753)
29 meta-analysis.mp. (17026)
30 quantitative review$.mp. (171)
31 quantitative overview$.mp. (36)
32 statistical pool$.mp. (82)
33 28 or 29 or 30 or 31 or 32 (21462)
34 27 and 33 (103)
35 paracetamol.mp. or exp
Acetaminophen/(4505)
36 34 and 35 (7)
37 limit 36 to yr ¼ ‘‘2002 - 2006’’ (6)
Samestrategywasused forMEDLINE,EMBASE,CINHAL
andAMED. InScienceCitation IndexandCochraneLib, how-
ever, we used key word search for every possible term and
combined them to obtain the relevant citations.
No further search for the lower level of evidence was
needed for paracetamol as there are a number of SRs/
MAs. However, for some modalities, such as weight loss
and massage, the search carried on with RCT/CT, or
cohort/caseecontrol/cross-sectional studies, using the
following alternative strategies.Database: Ovid MEDLINE(R) <2002 to January Week 1 2006>
Search strategy
1 exp Randomized Controlled Trials/or randomised
controlled trial.mp. or exp Clinical Trials/or exp
Random Allocation/(103055)
2 double blind.mp. or exp Double-Blind Method/(46335)
3 exp Single-Blind Method/or single blind.mp. (8025)
4 placebo.mp. or exp Placebos/(50690)
5 comparative Study/(519952)
6 1 or 2 or 3 or 4 or 5 (653644)
7 limit 6 to year¼ ‘‘2002 - 2006’’ (323312)
Database: Ovid MEDLINE(R) <2002 to January Week 1 2006>
Search strategy
1 exp Cohort Studies/(302725)
2 cohort stud$.mp. (57984)
3 exp Prospective Studies/(123278)
4 prospective stud$.mp. (134288)
5 relative risk$.mp. (19680)
6 incidence.mp. or exp INCIDENCE/(169499)
7 1 or 2 or 3 or 4 or 5 or 6 (457813)
8 exp Case-Control Studies/(206064)
9 case control stud$.mp. (65217)
10 exp Retrospective Studies/(148360)
11 retrospective stud$.mp. (152256)
12 exp Odds Ratio/(20377)
13 odds ratio$.mp. (48727)
14 8 or 9 or 10 or 11 or 12 or 13 (245705)
15 exp Cross-Sectional Studies/(45147)
16 cross sectional stud$.mp. (48194)
17 risk.mp. or exp RISK/(467774)
18 prevalence.mp. or exp PREVALENCE/(126109)
19 15 or 16 or 17 or 18 (569453)
20 7 or 14 or 19 (963666)
21 limit 20 to yr ¼ ‘‘2002 - 2006’’ (453748)
To search for economic evaluation, the following strategy
was used in combination with the search terms for OA and
paracetamol.
Database: Ovid MEDLINE(R) <2002 to January Week 1 2006>
Search strategy
1 ‘‘Costs and Cost Analysis’’/or Cost-Beneﬁt Analysis/
or ‘‘Quality of Life’’/(66609)
2 economic evaluation$.mp. (2102)
3 cost effectiveness anal$.mp. (2232)
4 cost utility anal$.mp. (449)
5 cost beneﬁt anal$.mp. (22265)
6 cost minimisation analysis.mp. (48)
7 exp Health Services Research/or exp Quality-
Adjusted Life Years/(46689)
8 1 or 2 or 3 or 4 or 5 or 6 or 7 (110077)
9 limit 8 to yr ¼ ‘‘2002 - 2006’’ (52844)
Appendix 3. Committee members’ disclosuresName Consulting fees, honoraria, research or in-
stitutional support, educational grants,
equipment, services or expenses
Ownership
interest
Business
relationship
Service with organisation
with interests comparable to
OARSI
Nothing to
declare
W. Zhang Nil Nil Nil Leader EULAR OA
task force
R.W. Moskowitz Adolor
Anesiva Bioiberica Bionocare
Endo
Merck
Novartis
Pﬁzer Rottapharm Sanoﬁ-Aventis
Nil Nil Nil
G. Nuki AstraZeneca Savient
Gelita Co
Nil Nil Nil
S. Abramson Amgen
GlaxoSmithKline
Merck
Novartis
Pﬁzer
Amgen
BMS
Merck
Pﬁzer
Resolvyx
Nil Nil
R.D. Altman Abbott
Anesiva
Ferring Kinicure
McNeil
Negma
Novartis
Pﬁzer
Proprius
Reliant
Rottapharm
Sanoﬁ-Aventis
Nil Nil Nil
N. Arden Merck, Sharp & Dohme
Novartis
Pﬁzer
Proctor & Gamble
Q-Med
Roche
Rottapharm
Schering-Plough
Servier
Nil Nil Nil
S. Bierma-Zeinstra Nil Nil Nil Nil U
K.D. Brandt Anesiva
Genzyme
Novartis
Pﬁzer
Pﬁzer Nil Nil
P. Croft Nil Nil Nil Nil U
M. Doherty AstraZeneca
GlaxoSmithKline
IDEA technology
Ipsen
Novartis
Reckitt
Nil Nil EULAR OA
task force
M. Dougados Abbott
AstraZeneca
BMS
CombinatoRx
Merck
Negma
Novartis
Oﬁzer
Pharmasciences
Proctor & Gamble
Roche
Wyeth
Nil Nil Nil
M. Hochberg Amgen
AstraZeneca
Bayer
Biogen idec
Bionicare
Bristol Myers Squibb
Appendix 3 (continued)Name Consulting fees, honoraria, research or in-
stitutional support, educational grants,
equipment, services or expenses
Ownership
interest
Business
relationship
Service with organisation
with interests comparable to
OARSI
Nothing to
declare
Chugai
CombinatoRx
Ferring
Genzyme
GlaxoSmithKline
Merck
NicOx
Novartis
Proctor & Gamble
Proprius
Roche
Sanoﬁ-Aventis
Wyeth
Nil Dainippon
Sumitomo
Nil
D.J. Hunter AstrZeneca
Donjoy
Merck
Pﬁzer
Stryker
Nil Nil Nil
K. Kwoh Beveridge Inst
GlaxoSmithKline
Novartis
TAP
Cartesia Nil Nil
L.S. Lohmander AstraZeneca
Centocor
GlaxoSmithKline
Pﬁzer
Nil Nil Nil
P. Tugwell Abbott
Almirall
AstraZeneca
Aventis
Berlex
Biomatrix
Bristol Myers
Squibb
Cadeuceus
Centocor
CIGNA
Dimedix
Dimethaid
IDRC
Eli Lilly
Genzyme
Glaxo-Welcome
GlaxoSmithKline
Hoechst Marion
Roussel
Innovus
Johnson&Johnson
Lilley
Medicus
Merck
Merck Frost
Novartis
Novopharm
Ortho McNeil
Parke Davis
Pennside
Pﬁzer
Rhone-Poulenc
Roche
Sandoz
Scios
Searle
SmithKline
Beecham
Teva
Wyeth Ayerst
Nil Nil Nil
996 W. Zhang et al.: OARSI recommendations for the management of hip and knee OAReferences
1. Peat G, McCarney R, Croft P. Knee pain and osteoar-
thritis in older adults: a review of community burden
and current use of primary health care [see comment]
[Review] [45 refs]. Ann Rheum Dis 2001 Feb;60(2):
91e7.
2. Felson DT, Naimark A, Anderson J, Kazis L,
Castelli W, Meenan RF. The prevalence of knee oste-
oarthritis in the elderly. The Framingham Osteoarthritis
Study. Arthritis Rheum 1987 Aug;30(8):914e8.
3. Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis.
Prevalence in the population and relationship between
symptoms and X-ray changes. Ann Rheum Dis 1966
Jan 1;25(1):1e24.
4. McAlindon TE, Snow S, Cooper C, Dieppe PA. Radio-
graphic patterns of osteoarthritis of the knee joint in the
community: the importance of the patellofemoral joint.
Ann Rheum Dis 1992 Jul;51(7):844e9.
5. O’Reilly SC, Muir KR, Doherty M. Screening for pain in
knee osteoarthritis: which question? Ann Rheum Dis
1996 Dec 1;55(12):931e3.
6. van Saase JL, van Romunde LK, Cats A,
Vandenbroucke JP, Valkenburg HA. Epidemiology of
osteoarthritis: zoetermeer survey. Comparison of ra-
diological osteoarthritis in a Dutch population with
that in 10 other populations. Ann Rheum Dis 1989
Apr 1;48(4):271e80.
7. Felson DT. Epidemiology of hip and knee osteoarthritis
[Review] [183 refs]. Epidemiol Rev 1988;10:1e28.
8. Ingvarsson T, Hagglund G, Lohmander LS. Preva-
lence of hip osteoarthritis in Iceland. Ann Rheum Dis
1999 Apr;58(4):201e7.
9. Lanyon P, Muir K, Doherty S, Doherty M. Assessment
of a genetic contribution to osteoarthritis of the hip: sib-
ling study [see comment]. BMJ 2000 Nov 11;
321(7270):1179e83.
10. Lawrence RC, Helmick CG, Arnett FC, Deyo RA,
Felson DT, Giannini EH, et al. Estimates of the preva-
lence of arthritis and selected musculoskeletal disor-
ders in the United States [see comment]. Arthritis
Rheum 1998 May;41(5):778e99.
11. Tepper S, Hochberg MC. Factors associated with hip
osteoarthritis: data from the First National Health and
Nutrition Examination Survey (NHANES-I). Am J Epi-
demiol 1993 May 15;137(10):1081e8.
12. Dawson J, Linsell L, Zondervan K, Rose P, Randall T,
Carr A, et al. Epidemiology of hip and knee pain and
its impact on overall health status in older adults.
Rheumatology 2004;43(4):497e504.
13. Mannoni A, Briganti MP, Di Bari M, Ferrucci L,
Costanzo S, Serni U, et al. Epidemiological proﬁle of
symptomatic osteoarthritis in older adults: a population
based study in Dicomano, Italy. Ann Rheum Dis 2003;
62(6):576e8.
14. Walker-Bone K, Javaid K, Arden N, Cooper C. Regular
review: medical management of osteoarthritis. BMJ
2000 Oct 14;321(7266):936e40.
15. Hunter DJ, Felson DT. Osteoarthritis. BMJ 2006 Mar
18;332(7542):639e42.
16. Altman RD, Hochberg MC, Moskowitz RW,
Schnitzer TJ. Recommendations for the medical man-
agement of osteoarthritis of the hip and knee: 2000 up-
date. Arthritis Rheum 2000;43(9):1905e15.
17. Jordan KM, Arden NK, Doherty M, Bannwarth B,
Bijlsma JW, Dieppe P, et al. EULAR recommendations
2003: an evidence based approach to themanagement of knee osteoarthritis: report of a Task
Force of the Standing Committee for International Clin-
ical Studies Including Therapeutic Trials (ESCISIT)
[Review] [82 refs]. Ann Rheum Dis 2003 Dec;62(12):
1145e55.
18. Zhang W, Doherty M, Arden N, Bannwarth B,
Bijlsma J, Gunther KP, et al. EULAR evidence based
recommendations for the management of hip osteoar-
thritis: report of a task force of the EULAR Standing
Committee for International Clinical Studies Including
Therapeutics (ESCISIT). Ann Rheum Dis 2005 May
1;64(5):669e81.
19. Pencharz JN, Grigoriadis E, Jansz GF, Bombardier C.
A critical appraisal of clinical practice guidelines for the
treatment of lower-limb osteoarthritis [Review] [33
refs]. Arthritis Res 2002;4(1):36e44.
20. Roddy E, Doherty M. Guidelines for management of
osteoarthritis published by the American College of
Rheumatology and the European League against
Rheumatism: why are they so different? Rheum Dis
Clin North Am 2003;29(4):717e31.
21. Wegman A, van der WD, van Tulder M, Stalman W, de
Vries T. Nonsteroidal antiinﬂammatory drugs or
acetaminophen for osteoarthritis of the hip or knee?
A systematic review of evidence and guidelines.
J Rheumatol 2004 Feb;31(2):344e54.
22. The AGREE Collaboration. Appraisal of Guidelines
for Research & Evaluation (AGREE) Instrument.
Available from: <www.agreecollaboration.org>;
2006.
23. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clini-
cal guidelines: developing guidelines [Review] [17
refs]. BMJ 1999 Feb 27;318(7183):593e6.
24. Oxman AD, Guyatt GH. Validation of an index of the
quality of review articles. J Clin Epidemiol 1991;
44(11):1271e8.
25. Jadad AR, Moore RA, Carroll D, Jenkinson C,
Reynolds DJ, Gavaghan DJ, et al. Assessing the
quality of reports of randomized clinical trials: is blind-
ing necessary? Control Clin Trials 1996 Feb;17(1):
1e12.
26. Hedges LV. Fitting continues models to effect size
data. J Educ Stat 1982;7:245e70.
27. Cohen J. Statistical Power Analysis for the Behavioral
Sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum
Associates 1988.
28. Whitehead A, Whitehead J. A general parametric
approach to the meta-analysis of randomized clinical
trials. Stat Med 1991 Nov;10(11):1665e77.
29. Cook RJ, Sackett DL. The number needed to treat:
a clinically useful measure of treatment effect. BMJ
1995;310(6977):452e4.
30. Altman DG. Conﬁdence intervals for the number
needed to treat. BMJ 1998 Nov 7;317(7168):1309e12.
31. Kleinbaum DG, Kuppler LL, Morgenstern H. Epidemio-
logic Research e Principles and Quantitative
Methods. John Willey & Sons, Inc. 1982.
32. Algorithms for the diagnosis and management of
musculoskeletal complaints. Am J Med 1997 Dec 29;
103(6 Suppl 1):S49e80.
33. Universe of Adult Patients with Osteoarthritis of the
Knee e Phase I and Phase II. American Academy
of Orthopaedic Surgons. Available from: <http://
www.aaos.org/>; 2003 [accessed on 17 Oct
2005].
34. Prodigy guidance e osteoarthritis. Prodigy, The UK
NHS, 2005. Available from: <http://www.prodigy.nhs.
997Osteoarthritis and Cartilage Vol. 15, No. 9uk/guidance.asp?gt¼Osteoarthritis> [accessed on 18
Oct 2005].
35. Medical management of adults with osteoarthritis.
Michigan Quality Improvement Consortium, 2005.
Available from: <www.mgic.org> [accessed on 17 Oct
2005].
36. Albright J, Allman R, Bonﬁglio RP, Conill A, Dobkin B,
Guccione AA, et al. Philadelphia panel evidence-
based clinical practice guidelines on selected rehabil-
itation interventions for knee pain. Phys Ther 2001;
81(10):1675e700.
37. Bennell K, Hinman R, Crossley K. APA knee joint
osteoarthritis poisition statement. Australian Physiother-
apy Association. Available from: <https://apa.advsol.
com.au/staticcontent/staticpages/position_statements/-
mpa/kneeOAsummary.pdf>; 2001 [accessed on 17 Oct
2005].
38. Bijl D, Diirven-Meijer PC, Opstelten W. General prac-
tice guidelines for non-traumatic knee complaints in
adults. Huisarts Wet 1998;41(7):344e50.
39. BrosseauL,WellsGA, Tugwell P, EganM,DuboulozCJ,
Casimiro L, et al. Ottawa panel evidence-based clinical
practice guidelines for therapeutic exercises andmanual
therapy in the management of osteoarthritis. Phys Ther
2005;85(9):907e71.
40. Eccles M, Freemantle N, Mason J. North of England
evidence based guideline development project: sum-
mary guideline for non-steroidal anti-inﬂammatory
drugs versus basic analgesia in treating the pain of de-
generative arthritis. BMJ 1998 Aug 22;317(7157):
526e30.
41. Enloe LJ, Shields RK, Smith K, Leo K, Miller B. Total
hip and knee replacement programs: a report using
consensus. J Orthop Sports Phys Ther 1996 Jan;
23(1):3e11.
42. Holbrook AM. Ontario treatment guidelines for osteo-
arthritis, rheumatoid arthritis and acute musculoskele-
tal injury. Ontario Program for Optimal Therapy.
Available from: <http://www.thecem.net/Downloads/
msk.pdf>; 2000 [accessed on 1 Sept 2005].
43. Lee J, Thorson D, Jurrison M, Hunt A, Harckom T,
Akerman S, et al. Health care guideline: diagnosis and
treatment of adult degenerative joint disease (DJD) of
the knee. Institute for Clinical System Improvement.
Available from: <www.icsi.org>; Nov 2004.
44. Lundebjerg N. Exercise prescription for older adults
with osteoarthritis pain: consensus practice recommen-
dations. J Am Geriatr Soc 2001;49(6):808e23.
45. Puhl W, Bernau A, Bohle E, Brune K, Gerhardt P,
Greitemann B, et al. Diagnosis and treatment of
knee osteoarthritis in outpatients [German]. Z Orthop
Ihre Grenzgeb 2000;138(1):85e93.
46. Rankin EA, Alarcon GS, Chang RW, Cooney LM Jr,
Costley LS, Delitto A, et al. NIH consensus statement
on total knee replacement December 8e10, 2003.
J Bone Joint Surg Am 2004;86(6):1328e35.
47. Roddy E, Zhang W, Doherty M, Arden NK, Barlow J,
Birrell F, et al. Evidence-based recommendations for
the role of exercise in the management of osteoarthri-
tis of the hip or kneedthe MOVE consensus. Rheu-
matology (Oxford) 2005 Jan;44(1):67e73.
48. Rosman HA, Tat KLK, Veerapen K, Suk Chyn G, Gek-
Liew DDRC, Hussein H, et al. Clinical practice guide-
lines on the management of osteoarthritis. Academy of
Medicine of Malaysia. Available from: <http://www.
acadmed.org.my/cpg/Bookleta.pdf>; 2002 [accessed
on 17 Oct 2005].49. Scott DL, Billingham M, Bourke BE, Bywaters EGL,
Dieppe PA, Doherty M, et al. Guidelines for the diag-
nosis, investigation and management of osteoarthritis
of the hip and knee e report of a joint working group
of the British-Society-For-Rheumatology and the Re-
search Unit of the Royal-College-of-Physicians. J R
Coll Physicians Lond 1993;27(4):391e6.
50. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An
evidence-based approach to prescribing NSAIDs in
the treatment of osteoarthritis and rheumatoid arthritis:
the second Canadian consensus conference [Review]
[111 refs]. Can J Clin Pharmacol 2000;7(Suppl A):
4Ae16A.
51. Vogels EMHM, Hendriks HJM, van Barr ME, Dekker J,
Hopman-Rock M, Oostendorp RAB, et al. Clinical
practice guidelines for physical therapy in patients
with osteoarthritis of the hip and knee. Available
from: <http://www.cebp.nl/media/m11.pdf>; 2003
[accessed on 20 Oct 2005].
52. Christensen R, Astrup A, Bliddal H. Weight loss: the
treatment of choice for knee osteoarthritis? A random-
ized trial. Osteoarthritis Cartilage 2005;13(1):20e7.
53. Lin J, Zhang W, Jones A, Doherty M. Efﬁcacy of topical
non-steroidal anti-inﬂammatory drugs in the treatment
of osteoarthritis: meta-analysis of randomised con-
trolled trials. Br Med J 2004 Aug 7;329(7461):324e6.
54. Bazian L. Arthroscopic lavage for osteoarthritis of the
knee. Evidence-based Healthcare & Public Health
2005;9(3):192e6.
55. Moseley JB, O’Malley K, Petersen NJ, Menke TJ,
Brody BA, Kuykendall DH, et al. A controlled trial of ar-
throscopic surgery for osteoarthritis of the knee. N
Engl J Med 2002;347(2):81e8. Date of publication:
11 Jul 2002.
56. Ethgen O, Bruyere O, Richy F, Dardennes C,
Reginster J-Y. Health-related quality of life in total
hip and total knee arthroplasty: a qualitative and sys-
tematic review of the literature. J Bone Joint Surg
Am 2004;86(5):963e74.
57. Virolainen P, Aro HT. High tibial osteotomy for the
treatment of osteoarthritis of the knee: a review of
the literature and a meta-analysis of follow-up studies.
Arch Orthop Trauma Surg 2004;124(4):258e61.
58. Ofman JJ, MacLean CH, Straus WL, Morton SC,
Berger ML, Roth EA, et al. A metaanalysis of severe
upper gastrointestinal complications of nonsteroidal
antiinﬂammatory drugs. J Rheumatol 2002;29(4):
804e12.
59. Evans JMM, McMahon AD, McGilchrist MM, White G,
Murray FE, McDevitt DG, et al. Topical non-steroidal
anti-inﬂammatory drugs and admission to hospital for
upper gastrointestinal bleeding and perforation: a re-
cord linkage caseecontrol study. BMJ 1995 Jul 1;
311(6996):22e6.
60. Juni P, Nartey L, Reichenbach S, Sterchi R,
Dieppe PA, Egger M. Risk of cardiovascular events
and rofecoxib: cumulative meta- analysis. Lancet
2004;364(9450):2021e9.
61. Capurso L, Koch M. Prevention of NSAID-induced
gastric lesions: H2 antagonists or misoprostol? A
meta-analysis of controlled clinical studies [Italian].
Clin Ter 1991 Dec 15;139(5e6):179e89.
62. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C,
Symmons D. The effectiveness of ﬁve strategies for
the prevention of gastrointestinal toxicity induced by
non-steroidal anti-inﬂammatory drugs: systematic re-
view. BMJ 2004 Oct 23;329(7472):948e52.
998 W. Zhang et al.: OARSI recommendations for the management of hip and knee OA63. Witt C, Selim D, Reinhold T, Jena S, Brinkhaus B,
Liecker B, et al. Cost-effectiveness of acupuncture in
patients with headache, low back pain and osteoarthri-
tis of the hip and the knee. In: 12th Annual Symposium
on Complementary Health Care e Abstracts,
19the21st September 2005, Exeter, UK. Focus on Al-
ternative and Complementary Therapies 2005, 10
(Suppl 1: 57e58).
64. Cochrane T, Davey RC, Matthes Edwards SM. Rand-
omised controlled trial of the cost-effectiveness of wa-
ter-based therapy for lower limb osteoarthritis. Health
Technol Assess 2005;9(31):iiiev.
65. Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C,
Symmons D. Preventing non-steroidal anti-
inﬂammatory drug-induced gastrointestinal toxicity:
are older strategies more cost-effective in the general
population? Rheumatology 2005 Dec 20;10.1093/
rheumatology/kei241
66. Torrance GW, Raynauld JP, Walker V,
Goldsmith CH, Bellamy N, Band PA, et al. A prospec-
tive, randomized, pragmatic, health outcomes trial
evaluating the incorporation of hylan G-F 20 into
the treatment paradigm for patients with knee osteo-
arthritis (part 2 of 2): economic results. Osteoarthritis
Cartilage 2002;10(7):518e27.
67. Chang RW, Pellissier JM, Hazen G-B. A cost-effec-
tiveness analysis of total hip arthroplasty for osteoar-
thritis of the hip (Structured abstract). JAMA 1996;
275:858e65.
68. Lavernia CJ, Guzman JF, Gachupin GA. Cost effec-
tiveness and quality of life in knee arthroplasty. Clin
Orthop Relat Res 1997;134e9.
69. Lohr KN, Field MJ. A provisional instrument for as-
sessing clinical practice guidelines. In: Field MJ,
Lohr KN, Eds. Guidelines for Clinical Practice. From
Development to Use. Washington DC: National Acad-
emy Press 1992.
70. Nevitt MC, Xu L, Zhang Y, Lui L-Y, Yu W, Lane NE,
et al. Very low prevalence of hip osteoarthritis among
Chinese elderly in Beijing, China, compared with
Whites in the United States: The Beijing osteoarthritis
study. Arthritis Rheum 2002;46(7):1773e9.
71. Black N. Evidence-based surgery: a passing fad?
World J Surg 1999;23(8):789e93.
72. Black N. Why we need observational studies to evalu-
ate the effectiveness of health care. BMJ 1996 May
11;312(7040):1215e8.
73. Buszewicz M, Rait G, Grifﬁn M, Nazareth I, Patel A,
Atkinson A, et al. Self-management of arthritis in pri-
mary care: randomised controlled trial. BMJ 2006
Oct 28;333(7574):879.
74. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR,
Hooper MM, et al. Glucosamine, chondroitin sulfate,
and the two in combination for painful knee osteoar-
thritis. N Engl J Med 2006;354(8):795e808.
75. Herrero-Beaumont G, Ivorra JA, Del Carmen
Trebado M, Blanco FJ, Benito P, Martin-Mola E,
et al. Glucosamine sulfate in knee osteoarthritis symp-
toms: a randomised, double-blind, placebo-controlled
study using acetaminophen as a side comparator.
Arthritis Rheum 2007;56(2):555e67.
76. Uebelhart D, Malaise M, Marcolongo R,
DeVathairell F, Piperno M, Mailleux E, et al. Intermit-
tent treatment of knee osteoarthritis with oral chondroi-
tin sulfate: a one-year, randomized, double-blind,
multicenter study versus placebo. Osteoarthritis Carti-
lage 2004;12(4):269e76.77. Fidelix TSA, Soares BGDO, Trevisani VM. Diacerein for
osteoarthritis. In: Fidelix TSA, Soares BGDO,
Trevisani VFM, Eds. Diacerein for osteoarthritis. Co-
chrane Database Syst Rev 2006;(1)10.1002/
14651858.CD005117.pub2.2006.
78. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthe-
sis in systematic reviews. Ann Intern Med 1997 Nov 1;
127(9):820e6.
79. Christensen R, Bartels EM, Astrup A, Bliddal H.
The effect of weight reduction in obese patients
diagnosed with knee osteoarthritis (OA): a systematic
review and meta-analysis. Ann Rheum Dis 2007;
66(4):433e9.
80. Mazieres B, Hucher M, Zaim M, Garnero P. Effect
of chondroitin sulfate in symptomatic knee osteoar-
thritis: a multicenter, randomized, double blind,
placebo-controlled study. Ann Rheum Dis 2007;
66(5):639e45.
81. Dougados M, Nguyen M, Berdah L, Mazieres B,
Vignon E, Lequesne M. Evaluation of the structure-
modifying effects of diacerein in hip osteoarthritis:
ECHODIAH, a three-year, placebo-controlled trial.
Arthritis Rheum 2001;44(11):2539e47.
82. Lequesne M, Berdah L, Gerentes I. Efﬁcacy and
tolerance of diacerhein in the treatment of gonarthrosis
and coxarthrosis. Rev Prat 1998;48(17 Suppl).
Suppl 5.
83. Nguyen M, Dougados M, Berdah L, Amor B. Diacer-
hein in the treatment of osteoarthritis of the hip. Arthri-
tis Rheum 1994;37(4):529e36.
84. Pelletier J-P, Yaron M, Haraoui B, Cohen P,
Nahir MA, Choquette D, et al. Efﬁcacy and safety of
diacerein in osteoarthritis of the knee: a double-blind,
placebo-controlled trial. Arthritis Rheum 2000;43(10):
2339e48.
85. Pham T, Le Henanff A, Ravoud P, Dieppe P,
Paolozzi L, Dougados M. Evaluation of the symptom-
atic and structural efﬁcacy of a new hyaluronic acid
compound, NRD101, in comparison with diacerein
and placebo in a 1 year randomised controlled study
in symptomatic knee osteoarthritis. Ann Rheum Dis
2004;63(12):1611e7.
86. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of
indirect comparison for estimating efﬁcacy of
competing interventions: empirical evidence from
published meta-analyses. BMJ 2003 Mar 1;
326(7387):472.
87. DerSimonian R, Levine RJ. Resolving discrepancies
between a meta-analysis and a subsequent large con-
trolled trial. JAMA 1999;282(7):664e70.
88. Concato J, ShahN, Horwitz RI. Randomized, controlled
trials, observational studies, and the hierarchy of
research designs. N Engl J Med 2000;342(25):
1887e92.
89. Chodosh J, Morton SC, Mojica W, Maglione M,
Suttorp MJ, Hilton L, et al. Meta-analysis: chronic dis-
ease self-management programs for older adults. Ann
Intern Med 2005;143(6):427e38.
90. Warsi A, LaValley MP, Wang PS, Avorn J,
Solomon DH. Arthritis self-management education
programs: a meta-analysis of the effect on pain
and disability. Arthritis Rheum 2003 Aug;48(8):
2207e13.
91. Roddy E, Zhang W, Doherty M. Aerobic walking or
strengthening exercise for osteoarthritis of the knee?
A systematic review. Ann Rheum Dis 2005 Apr 1;
64(4):544e8.
999Osteoarthritis and Cartilage Vol. 15, No. 992. Stener-Victorin E, Kruse-Smidje C, Jung K. Compari-
son between electro-acupuncture and hydrotherapy,
both in combination with patient education and
patient education alone, on the symptomatic treatment
of osteoarthritis of the hip. Clin J Pain 2004;20(3):
179e85.
93. Brosseau L. Efﬁcacy of balneotherapy for osteoarthri-
tis of the knee: a systematic review. Phys Ther Rev
2002 Dec;7(4):209e22.
94. NguyenM,RevelM,DougadosM.Prolongedeffects of 3
week therapy in a spa resort on lumbar spine, knee and
hip osteoarthritis: follow-upafter 6months. A randomized
controlled trial. Br J Rheumatol 1997;36(1):77e81.
95. Messier SP, Loeser RF, Miller GD, Morgan TM,
Rejeski WJ, Sevick MA, et al. Exercise and dietary
weight loss in overweight and obese older adults
with knee osteoarthritis: the arthritis, diet, and activity
promotion trial. Arthritis Rheum 2004;50(5):1501e10.
96. Soeken KL, Lee WL, Bausell RB, Agelli M,
Berman BM. Safety and efﬁcacy of S-adenosylmethio-
nine (SAMe) for osteoarthritis e a meta-analysis.
J Fam Pract 2002;51(5):425e30.
97. Brosseau L. Efﬁcacy of transcutaneous electrical
nerve stimulation for osteoarthritis of the lower extrem-
ities: a meta-analysis. Phys Ther Rev 2004 Dec;9(4):
213e33.
98. Bjordal JM,CouppeC,ChowRT,TunerJ, LjunggrenEA.
A systematic review of low level laser therapy with loca-
tion-speciﬁc doses for pain from chronic joint disorders.
Aust J Physiother 2003;49(2):107e16.
99. Welch V, Brosseau L, Peterson J, Shea BJ, Tugwell P,
Wells G. Therapeutic ultrasound for osteoarthritis of
the knee. Cochrane Database Syst Rev 2001;(3).
CD003132.
100. Kresnik E, Mikosch P, Gallowitsch HJ, Jesenko R,
Just H, Kogler D, et al. Clinical outcome of radiosyno-
viorthesis: a meta-analysis including 2190 treated
joints. Nucl Med Commun 2002;23(7):683e8.
101. Brosseau L, Judd MG, Marchand S, Robinson VA,
Tugwell P, Wells G, et al. Thermotherapy for treatment
of osteoarthritis. The Cochrane Library (Oxford) 2003;
4 (ID #CD004522).
102. Bennell KL, Hinman RS, Metcalf BR, Buchbinder R,
McConnell J, McColl G, et al. Efﬁcacy of physiother-
apy management of knee joint osteoarthritis: a rando-
mised, double blind, placebo controlled trial. Ann
Rheum Dis 2005;64(6):906e12.
103. Brouwer RW, Jakma TSC, Verhagen AP,
Verhaar JAN, Bierma-Zeinstra SMA. Braces and or-
thoses for treating osteoarthritis of the knee. Cochrane
Database Syst Rev 2005;(1)10.1002/14.2005.
104. Hulme JM, Judd MG, Robinson VA, Tugwell P,
Wells G, de Bie RA. Electromagnetic ﬁelds for the
treatment of osteoarthritis. Cochrane Database Syst
Rev 2002;(1)10.1002/14651858.2002.
105. Zhang W, Jones A, Doherty M. Does paracetamol
(acetaminophen) reduce the pain of osteoarthritis? A
meta-analysis of randomised controlled trials. Ann
Rheum Dis 2004;63(8):901e7.
106. Towheed TE, Hochberg MC, Judd MG, Wells G. Acet-
aminophen for osteoarthritis. The Cochrane Library
(Oxford) 2002;4 (ID #CD004257).
107. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-
steroidal anti-inﬂammatory drugs, including cyclo-
oxygenase-2 inhibitors, in osteoarthritic knee pain:
meta-analysis of randomised placebo controlled trials.
Br Med J 2004;329(7478):1317e20.108. Lee C, Hunsche E, Balshaw R, Kong SX,
Schnitzer TJ. Need for common internal controls
when assessing the relative efﬁcacy of pharmacologic
agents using a meta-analytic approach: case study
of cyclooxygenase 2-selective inhibitors for the treat-
ment of osteoarthritis. Arthritis Care Res 2005;53(4):
510e8.
109. Zhang WY, Li Wan PA. The effectiveness of topically
applied capsaicin. A meta-analysis. Eur J Clin Phar-
macol 1994;46(6):517e22.
110. Bellamy N, Campbell J, Robinson V, Gee T,
Bourne R, Wells G. Intraarticular corticosteroid for
treatment of osteoarthritis of the Knee. The Cochrane
Library (Oxford) 2005;4 (ID #CD005328).
111. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-
articular hyaluronic acid in treatment of knee osteoar-
thritis: a meta-analysis. J Am Med Assoc 2003;
290(23):3115e21.
112. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K,
Mullner M. Intra-articular hyaluronic acid for the treat-
ment of osteoarthritis of the knee: systematic review
and meta-analysis. Can Med Assoc J 2005;172(8):
1039e43.
113. Towheed TE, Maxwell L, Anastassiades TP, Shea B,
Houpt J, Robinson V, et al. Glucosamine therapy for
treating osteoarthritis. The Cochrane Library (Oxford)
2005;4 (ID #CD002946).
114. Richy F, Bruyere O, Ethgen O, Cucherat M,
Henrotin Y, Reginster J-Y. Structural and symptomatic
efﬁcacy oS100f glucosamine and chondroitin in knee
osteoarthritis: a comprehensive meta-analysis. Arch
Intern Med 2003;163(13):1514e22.
115. Ernst E. Avocado-soybean unsaponiﬁables (ASU) for
osteoarthritis e a systematic review. Clin Rheumatol
2003;22(4e5):285e8.
116. Gagnier JJ, Chrubasik S, Manheimer E. Harpgophy-
tum procumbens for osteoarthritis and low back
pain: a systematic review. BMC Altern Med 2004;
4:10.
117. Nizard RS, Biau D, Porcher R, Ravaud P, Bizot P,
Hannouche D, et al. A meta-analysis of patellar re-
placement in total knee arthroplasty. Clin Orthop
2005;196e203.
118. Garcia Rodriguez LA, Hernandez-Diaz S. Relative
risk of upper gastrointestinal complications among
users of acetaminophen and nonsteroidal anti-
inﬂammatory drugs. Epidemiology 2001 Sep;12(5):
570e6.
119. Lewis SC, Langman MJS, Laporte J-R, Matthres NS,
Rawlins MD, Wiholm B-E. Doseeresponse relation-
ships between individual nonaspirin nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and serious upper
gastrointestinal bleeding: a meta-analysis based on in-
dividual patient data. Br J Clin Pharmacol 2002;54:
320e6.
120. Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ,
Youngman LD, Gaziano JM. Analgesic use and
renal function in men. JAMA 2001 Jul 18;286(3):
315e21.
121. Fored CM, Ejerblad E, Lindblad P, Fryzek JP,
Dickman PW, Signorello LB, et al. Acetaminophen, as-
pirin and chronic renal failure. N Engl J Med 2001 Dec
20;345(25):1801e8.
122. Hernandez-Diaz S, Varas-Lorenzo C, Garcia
Rodriguez LA. Non-steroidal antiinﬂammatory drugs
and the risk of acute myocardial infarction. Basic Clin
Pharmacol Toxicol 2006;98(3):266e74.
1000 W. Zhang et al.: OARSI recommendations for the management of hip and knee OA123. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P,
Beasley R. Risk of cardiovascular events and cele-
coxib: a systematic review and meta-analysis. J R
Soc Med 2006;99(3):132e40.
124. Aldington S, Shirtcliffe P, Weatherall M, Beasley R.
Increased risk of cardiovascular events withparecoxib/valdecoxib: a systematic review and meta-
analysis. N Z Med J 2005;118(1226):10.
125. Kalso E, Edwards JE, Moore RA, Mcquay HJ.
Opioids in chronic non-cancer pain: systematic
review of efﬁcacy and safety. Pain 2004;112(3):
372e80.
